Nurse Mpho Matloane prepares a syringe crammed with the drug Lenacapavir which he prepares to manage to Kegoratile Aphane (left) on the Phedisong clinic in Ga-Rankuwa, north-west of Pretoria, on Dec. 2, 2025.
Ihsaan Haffe/AFP through Getty Photographs
cover caption
toggle caption
Ihsaan Haffe/AFP through Getty Photographs
JOHANNESBURG — South Africa rolled out a brand new, biannual HIV prevention drug on Friday that has the potential to drastically reduce an infection charges, however U.S. help cuts imply entry can be restricted.
Lenacapavir, a form of Pre-exposure Prophylaxis (PrEP), is injected into the abdomen each six months and is mainly failproof at stopping high-risk people from contracting the virus.
South Africa is just not the primary African nation to introduce injectable Lenacapavir. The drug is rolling out throughout Africa sooner than any HIV prevention choice to date, and South Africa turns into the ninth nation on the continent to launch it. However in a nation with the very best variety of HIV instances on the earth, the long-acting injection is being hailed as a possible sport changer.
“The launch today of Lenacapavir marks a turning point in our nation’s fight against HIV. To us, this incredible, incredible treatment is not just a medicine or a drug, to us it represents a major turning point in South Africa’s national story,” stated South African President Cyril Ramaphosa on the launch.
The rollout is starting in 360 well being amenities in high-burden districts.
South Africa, which has about 8 million individuals dwelling with HIV, in accordance with UNAIDS, has made nice strides in therapy, with a majority of the inhabitants on Antiretroviral medication. However prevention remains to be a difficulty, with about 160,000 new infections yearly.
Most of these infections happen in adolescent ladies and younger ladies aged 15 to 24, with about 1,000 on this demographic contaminated every week. Among the many causes for this are unequal relationships, typically transactional, that these women and girls have with older males.
South Africa already has some PrEP within the type of a each day tablet, however adherence is an issue. Specialists are hopeful that Lenacapavir might be the breakthrough that makes prevention simpler and accessible.
“Lenacapavir gives us something we have never had before in HIV prevention: a twice-yearly option that might be significantly easier to fit into people’s lives,” Dr. Saiqa Mullick, a PrEP specialist at Wits RHI on the College of Witwatersrand, instructed NPR.
However to actually flip the tide on the epidemic, Mullick says South Africa will want excess of what Worldwide well being financing partnership the World Fund has offered — sufficient to place about 456,000 individuals on the drug over two years.
“We have a game-changing technology, but impact will depend on implementation. A breakthrough product only changes the epidemic if it reaches the people who need it most,” she stated.
At the moment, entry is being hampered by two issues: the very fact the Trump administration slashed the U.S. President’s Emergency Plan for AIDS Aid (PEPFAR) funding to South Africa final yr, and the shortage of an inexpensive generic.
“U.S. funding cuts have affected HIV prevention infrastructure, community programmes, outreach, youth services and key population services. The cuts have undermined prevention programmes just as South Africa needs them for Lenacapavir rollout,” stated Mullick. “Some replacement financing is emerging but it doesn’t fully replace the scale of PEPFAR funding.”
Linda-Gail Bekker, an HIV professional who leads the Desmond Tutu Well being Basis, additionally famous the influence of the U.S. cuts.
“Had Pepfar been in place, we would have I think been the recipients of more Len doses, as it happens, we’re getting at least some from the Global Fund, but clearly we would have been able to receive both Global Fund as well as Pepfar support in this regard,” she stated.
At the moment the price of Lenacapavir, made by U.S. pharmaceutical firm Gilead, is prohibitive: about $28,000 per particular person a yr within the U.S.
However generics are on the best way after a deal to make them accessible to 120 low and middle-income nations, says Mullick. And sub-Saharan African nations are a precedence.
“South Africa is also seeking local manufacturing capacity to improve regional access and reduce dependency on external supply,” she stated.
The generic model of Lenacapavir is anticipated to turn out to be accessible in 2027 at a price of round $40 per particular person per yr.
“Clearly once the generics come online we’re very hopeful that the South African government will also be able to make a large contribution towards purchasing Len on a larger scale,” stated Bekker.
Scientific modeling reveals that if one to 2 million HIV-negative individuals take the shot between now and 2043, AIDS might stop to be a serious public well being drawback in South Africa.
